Arrowhead Pharmaceuticals Dirección

Dirección controles de criterios 3/4

El CEO de Arrowhead Pharmaceuticals' es Chris Anzalone , nombrado en Dec 2007, tiene una permanencia de 16.33 años. compensación anual total es $9.92M, compuesta por 9.1% salario y 90.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 3% de las acciones de la empresa, por valor de $81.25M. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 13.4 años, respectivamente.

Información clave

Chris Anzalone

Chief Executive Officer (CEO)

US$9.9m

Compensación total

Porcentaje del salario del CEO	9.1%
Permanencia del CEO	16.4yrs
Participación del CEO	3.0%
Permanencia media de la dirección	5.9yrs
Promedio de permanencia en la Junta Directiva	13.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Anzalone en comparación con los beneficios de Arrowhead Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$471m
Dec 31 2023	n/a	n/a	-US$297m
Sep 30 2023	US$10m	US$903k	-US$205m
Jun 30 2023	n/a	n/a	-US$181m
Mar 31 2023	n/a	n/a	-US$150m
Dec 31 2022	n/a	n/a	-US$155m
Sep 30 2022	US$12m	US$863k	-US$176m
Jun 30 2022	n/a	n/a	-US$154m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	n/a	n/a	-US$183m
Sep 30 2021	US$25m	US$837k	-US$141m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$110m
Dec 31 2020	n/a	n/a	-US$103m
Sep 30 2020	US$14m	US$786k	-US$85m
Jun 30 2020	n/a	n/a	-US$24m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	n/a	n/a	US$53m
Sep 30 2019	US$2m	US$674k	US$68m
Jun 30 2019	n/a	n/a	US$46m
Mar 31 2019	n/a	n/a	US$10m
Dec 31 2018	n/a	n/a	-US$29m
Sep 30 2018	US$2m	US$643k	-US$54m
Jun 30 2018	n/a	n/a	-US$54m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	n/a	n/a	-US$35m
Sep 30 2017	US$2m	US$616k	-US$34m

Compensación vs. Mercado: La compensación total de Chris($USD9.92M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD2.69M).

Compensación vs. Ingresos: La compensación de Chris ha sido consistente con los resultados de la empresa en el último año.

CEO

Chris Anzalone (54 yo)

16.4yrs

Permanencia

US$9,918,093

Compensación

Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christopher Anzalone	CEO, President & Director	16.4yrs	US$9.92m	3% $ 82.2m
Kenneth Myszkowski	Chief Financial Officer	14.3yrs	US$3.12m	0.19% $ 5.2m
Patrick O'Brien	COO, General Counsel & Secretary	9.4yrs	US$3.31m	0.23% $ 6.3m
James Hamilton	Chief of Discovery & Translational Medicine	no data	US$3.05m	0.17% $ 4.5m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	sin datos	sin datos
Vincent Anzalone	Head of Investor Relations & VP	no data	sin datos	sin datos
Howard Lovy	Director of Communications	18.8yrs	sin datos	sin datos
Bruce Given	Chief Medical Scientist	less than a year	US$16.34m	sin datos
Mark Seefeld	Head of Toxicology & VP	no data	sin datos	sin datos
Tracie Oliver	Chief Commercial Officer	1.9yrs	US$2.97m	0.0073% $ 199.0k
Aaron Tan	Head of Tax	2.3yrs	sin datos	sin datos
Nadia Meshkova	VP & Treasurer	2.3yrs	sin datos	sin datos

5.9yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0HI3 es experimentado (5.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christopher Anzalone	CEO, President & Director	16.4yrs	US$9.92m	3% $ 82.2m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	sin datos	sin datos
Douglass Given	Chairman of the Board	13.5yrs	US$474.60k	0.11% $ 3.1m
Michael Perry	Independent Lead Director	12.4yrs	US$459.60k	0.074% $ 2.0m
William Waddill	Independent Director	6.3yrs	US$469.60k	0.027% $ 727.4k
Ching-Lung Lai	Member of Hepatitis B Clinical Advisory Board	no data	sin datos	sin datos
Robert Gish	Chairman of Hepatitis B Clinical Advisory Board	no data	sin datos	sin datos
Mauro Ferrari	Independent Director	13.8yrs	US$459.60k	0.037% $ 1.0m
Jeffrey Teckman	Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board	no data	sin datos	sin datos
Stephen Locarnini	Member of Hepatitis B Clinical Advisory Board	no data	sin datos	sin datos
Johnson Lau	Member of Hepatitis B Clinical Advisory Board	no data	sin datos	sin datos
Carlo Ferrari	Member of Hepatitis B Clinical Advisory Board	no data	sin datos	sin datos

13.5yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 0HI3 son experimentados ( 13.4 años antigüedad media).

Arrowhead Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Chief Financial Officer recently sold US$1.4m worth of stock

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Chief Medical Officer recently sold US$567k worth of stock

Chief Financial Officer recently sold US$543k worth of stock

Chairman of the Board recently sold US$266k worth of stock

Recent updates

Now 22% undervalued after recent price drop

Second quarter 2024 earnings released: US$1.04 loss per share (vs US$0.46 profit in 2Q 2023)

Now 23% undervalued after recent price drop

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Chief Financial Officer recently sold US$1.4m worth of stock

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Now 27% overvalued after recent price rise

First quarter 2024 earnings released: US$1.24 loss per share (vs US$0.39 loss in 1Q 2023)

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million.

New major risk - Financial position

New major risk - Financial position

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.67 loss in FY 2022)

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Chief Medical Officer recently sold US$567k worth of stock

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.96 loss per share (vs US$0.68 loss in 3Q 2022)

New minor risk - Insider selling

Chief Financial Officer recently sold US$543k worth of stock

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Chairman of the Board recently sold US$266k worth of stock

Second quarter 2023 earnings released: EPS: US$0.46 (vs US$0.42 in 2Q 2022)

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Insufficient new directors

Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

No longer forecast to breakeven

Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Second quarter 2022 earnings released: EPS: US$0.41 (vs US$0.26 loss in 2Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors

Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical Study of Investigational ARO-ANG3 for the Treatment of Patients with Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Inc. Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Arrowhead Pharmaceuticals Inc Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Independent Director recently sold US$291k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Chairman of the Board recently sold US$326k worth of stock

Chief Commercial Officer James Hassard has left the company

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.13 loss in 3Q 2020)

Arrowhead Pharmaceuticals, Inc. Pauses ARO-ENaC Phase 1/2 Clinical Study

Arrowhead Pharmaceuticals, Inc. Initiates Phase 2B Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

Chief Commercial Officer recently sold US$323k worth of stock

Arrowhead Pharmaceuticals, Inc. Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH At EASL International Liver Congress

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia

Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.20 loss in 2Q 2020)

Arrowhead Pharmaceuticals Inc. Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease

Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

Chairman of the Board recently sold US$100k worth of stock

First quarter 2021 earnings released: US$0.20 loss per share (vs US$0.028 loss in 1Q 2020)

Revenue misses expectations

Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia

Chief Financial Officer recently sold US$1.1m worth of stock

Chairman of the Board recently sold US$759k worth of stock